Zymo Research Launches Quick-cfRNA™ Serum & Plasma Kit Ideal for RT-qPCR, Next Generation Sequencing and Liquid Biopsy Research

Purifies cfRNA from a variety of biological fluids

News provided by

Oct 18, 2016, 01:00 ET

VANCOUVER, British Columbia, Oct. 18, 2016 /PRNewswire/ -- Zymo Research Corporation will launch its Quick-cfRNA^™ Serum & Plasma Kit, which is currently in beta test, at ASHG 2016, Booth #112. Genetic researchers who need a reliable and robust method to purify cell-free RNA (cfRNA) from up to 1 ml of plasma, serum, or other biological fluids can use the Quick-cfRNA^™ Serum & Plasma Kit. Isolated RNA is immediately ready for sensitive downstream applications including RT-qPCR and Next Generation Sequencing. The kit enables simple, reliable, and efficient preparation of high-quality circulating cell-free RNA (including protein-bound, exosomal, miRNA and other small RNAs) from serum, plasma, amniotic fluid, cerebrospinal fluid, saliva, and other biological fluids. Cell-free RNA naturally occurs in blood and has clinical significance. It is becoming a promising tool for non-invasive and cost effective detection of cancer and other diseases.

A Zymo Research scientist testing the new Quick-cfRNA(TM) Serum & Plasma Kit.

In addition to the new Quick-cfRNA Serum & Plasma Kit, Zymo Research will also be showing its Quick-cfDNA^™Serum & Plasma Kit. Investigators are finding that increased rates of circulating cell-free DNA (cfDNA) from tumors can be used as a biomarker source for early cancer diagnosis, prognosis, and monitoring of cancer therapy. Zymo Research's Quick-cfDNA^™ Serum & Plasma Kit can be used for biomarker discovery and advanced liquid biopsy research. Liquid biopsies typically screen for free-floating pieces of DNA or RNA from cancerous cells found in the bloodstream. Researchers will capture a biological sample, such as blood or serum for disease analysis, and use that sample for a range of research applications such as RT-PCR, digital PCR, and Next Generation Sequencing. Translational genomic research is utilizing cfDNA to monitor personalized therapies based on specific tumor profiles. For these applications it is critical to recover total DNA. Zymo's Quick-cfDNA^™Serum & Plasma Kit uses a combination of chemical and enzymatic methods to efficiently recover total DNA (including cell-free apoptotic, necrotic, mitochondrial and viral DNA) linearly from up to 10 ml of sample.

Zymo Research's Zymo-Spin^™ technology is featured in both kits. Its unique spin-column design allows for ultra-pure DNA or RNA to be eluted in as little as 35 μl of water. The resulting DNA or RNA is suitable for all subsequent analyses and molecular manipulations, such as qPCR, Next Generation Sequencing, and DNA methylation analyses.

About Zymo Research Corporation
Zymo Research Corporation is a privately held company based in Irvine, California, USA. Since its inception in 1994 it has been serving the academic and biopharmaceutical scientific communities by providing DNA and RNA purification products. Their goal is to help scientists reduce time in the lab by eliminating steps and making the entire DNA/RNA extraction process simpler and faster. In addition to the nucleic acid purification products, Zymo Research also offers genetic, epigenetic and transcriptome analysis services. Zymo Research provides high quality products that are simple to use yet robust in their performance. For more information, please visit: www.zymoresearch.com. Follow Zymo Research Corporation on Facebook, LinkedIn, Twitter, and Instagram.

All trademarks are the property of their respective owners. Zymo Research Corporation, the stylized logo, tagline "The Beauty of Science is to Make Things Simple", Quick-cfDNA, Quick-cfRNA, and Zymo-Spin are trademarks of Zymo Research Corporation and are registered with the USPTO.

Photo - http://photos.prnewswire.com/prnh/20161014/429018
Logo - http://photos.prnewswire.com/prnh/20160506/364743LOGO

SOURCE Zymo Research Corp.